JP2017154974A - Glycerophospholipid-containing powder and tablets containing the same - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a glycerophospholipid-containing powder with excellent tableting property to reduce occurrence of troubles in tableting such as sticking and laminating, as well as to provide tablets containing glycerophospholipid at a high concentration.SOLUTION: Means for solving the above problem is that the glycerophospholipid-containing powder comprises the following ingredients (A)-(C), thereby occurrence of tableting troubles such as sticking and laminating is suppressed in manufacturing tablets containing glycerophospholipid-containing powder at a high concentration: (A) 10-80 mass% of glycerophospholipid; (B) 5-50 mass% of a non-calcined coral calcium powder; and (C) 0.01-10 mass% of a lubricant.SELECTED DRAWING: None

Description

  The present invention relates to a powder containing glycerophospholipid and a tablet containing the same.

  Various physiologically active substances are marketed in various forms such as drinks and soft capsules as health foods. From the viewpoint of superior portability, storage stability, manufacturing cost, etc., powder raw materials such as hard capsules, tablets, and granules are used. The product type used occupies most of the market.

  Glycerophospholipid is a phospholipid having a glycerol skeleton, and has attracted attention as a physiologically active substance that plays various roles in vivo. As its physiological activity, for example, an action of improving lipid metabolism (Patent Document 1) and prevention / improvement of liver damage (Patent Document 2) have been reported. Particularly in recent years, phosphatidylserine has been found to have a brain function improving effect and is considered promising as a health food material.

  From such a background, tablets containing glycerophospholipids have been demanded, but when tablets are produced using commercially available powders containing glycerophospholipids, there is a problem that tableting troubles such as sticking and laminating occur. there were.

  Usually, in order to solve these tableting obstacles, the effect of the glycerophospholipid-containing powder may be reduced by diluting the glycerophospholipid-containing powder with a large amount of excipient or the like. However, in this solution, since the content of glycerophospholipid in the tablet decreases, it is necessary to increase the tablet weight or the number of intake grains in order to obtain the recommended intake of glycerophospholipid. is there. Therefore, a new problem arises that the burden on the consumer and the manufacturing cost increase.

  In addition to commercially available glycerophospholipid-containing powders, patent documents disclose powders containing glycerophospholipids. For example, Patent Document 3 discloses a phosphatidylserine-containing powder containing phosphatidylserine, cyclodextrin, gelatin, and sucrose fatty acid ester. However, although the phosphatidylserine-containing powder improves dispersibility in water, it cannot suppress tableting troubles such as sticking and laminating.

  Patent Document 4 discloses a phosphatidylserine-containing powder containing phosphatidylserine and a calcium compound selected from the group consisting of calcined calcium, calcium oxide, and tricalcium phosphate. However, although this phosphatidylserine-containing powder enhances the storage stability of phosphatidylserine, it has not been able to sufficiently suppress tableting troubles such as sticking and laminating.

JP 2004-337177 A Japanese Patent Laid-Open No. 10-84879 JP 2013-143913 A International Publication No. 2011/142445

An object of the present invention is to provide a glycerophospholipid-containing powder having excellent tableting properties and to suppress the occurrence of tableting troubles such as sticking and laminating.
Another object of the present invention is to provide a tablet containing glycerophospholipid at a high concentration.

As a result of intensive studies to solve the above problems, the present inventors have solved the above problems by containing glycerophospholipids, unfired coral calcium powder, and lubricants at specific contents. As a result, the present invention has been completed.
That is, the present invention includes the following [1] to [4].

[1]
A glycerophospholipid-containing powder containing the following components (A) to (C).
(A) Glycerophospholipid 10-80 mass%
(B) Unbaked coral calcium powder 5-50 mass%
(C) Lubricant 0.01 to 10% by mass
[2]
further,
(D) Anti-caking agent 0.01 to 10% by mass
The glycerophospholipid-containing powder according to [1], comprising:
[3]
further,
(E) The glycerophospholipid-containing powder according to [1] or [2], which contains a disintegrant.
[4]
[1] A tablet containing the glycerophospholipid-containing powder according to any one of [3].

According to the present invention, a glycerophospholipid-containing powder having excellent tabletability can be provided. By tableting the glycerophospholipid-containing powder of the present invention, the occurrence of tableting troubles such as sticking and laminating can be suppressed.
In addition, according to the present invention, a tablet containing glycerophospholipid at a high concentration can be provided.

Hereinafter, the present invention will be described in more detail.
[Glycerophospholipid-containing powder]
The glycerophospholipid-containing powder of the present invention is a powder containing glycerophospholipid (A), unfired coral calcium powder (B), and lubricant (C).

<Glycerophospholipid (A)>
The glycerophospholipid used in the present invention is a compound having a structure in which a fatty acid-derived acyl group is present at the 1- and 2-positions of glycerin and a polar group containing phosphoric acid is bound at the 3-position. Specific examples include phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidic acid (PA) and the like, and a mixture of two or more thereof may be used. Preferably, it is phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidic acid (PA) or a mixture of two or more thereof.

As the glycerophospholipid (A), one extracted and purified from animals and plants can be used. Examples thereof include plants such as soybean, rice, corn, rapeseed, cottonseed, wheat, sunflower, safflower, and animals such as egg yolk and seafood. Or it can also obtain by a chemical reaction, an enzyme reaction, etc., and what is marketed as a reagent or a raw material can also be used.
Commercially available products include, for example, “Ultra Rec P” from ADM Japan, “LIPAMINE-PS70PN”, “LIPAMINE-PS70PN”, “BHN PS-20P”, BH "Nichiyu PS series" manufactured by Co., Ltd. and the like can be mentioned.

  The content of glycerophospholipid (A) contained in the glycerophospholipid-containing powder of the present invention is 10 to 80% by mass, preferably 12 to 70% by mass, and more preferably 15 to 60% by mass. When the glycerophospholipid (A) is less than 10% by mass, the active ingredient per tablet when blended in a tablet is reduced, and the number of ingested grains must be increased, which is a heavy burden for consumers. On the other hand, when glycerophospholipid (A) exceeds 80 mass%, there exists a possibility that powder may solidify by the adhesiveness of glycerophospholipid. Moreover, the problem that fluidity | liquidity and the uniform mixing property with another powder fall arises. Furthermore, when manufacturing tablets, tableting troubles such as sticking are likely to occur.

  As a component of glycerophospholipid (A), it is preferable to contain 30 mass% or more of phosphatidylserine (PS), More preferably, it is 50 mass% or more, More preferably, it is 60 mass% or more, Especially preferably, 70 mass % Or more.

<Unbaked coral calcium powder (B)>
The unfired coral calcium powder used in the present invention is a calcium-containing powder derived from reef-building corals collected from the seabed. Examples of commercially available products include “Coral Calcium Powder CCP” and “Coral Mineral Powder SMP” from Marine Bio, and “Coral Powder FM” from Kyowa Hakko Bio.

  The reef-building coral has mainly calcium carbonate as a calcium component, and when calcined, the calcium carbonate changes to calcium oxide. That is, the definition of “unfired” can be expressed by the content of calcium carbonate. In the present invention, “unfired coral calcium powder (B)” means that the content of calcium carbonate is 10% by mass or more. Means coral calcium powder. The content of calcium carbonate is preferably 25% by mass or more, more preferably 40% by mass or more, and particularly preferably 70% by mass or more.

  Content of the unbaked coral calcium powder (B) contained in the glycerophospholipid-containing powder of the present invention is 5 to 50% by mass, preferably 10 to 35% by mass, and more preferably 15 to 25% by mass. is there. When the unbaked coral calcium powder (B) is less than 5% by mass, the occurrence of tableting troubles such as sticking and laminating cannot be sufficiently suppressed when a glycerophospholipid-containing powder tablet is produced. On the other hand, when unbaked coral calcium powder (B) exceeds 50 mass%, content of glycerophospholipid cannot be raised.

<Lubricant (C)>
The lubricant (C) used in the present invention is contained in order to suppress sticking when producing a glycerophospholipid-containing powder tablet. For example, magnesium stearate, calcium stearate, sucrose fatty acid ester, Examples include glycerin fatty acid esters.

  The content of the lubricant (C) with respect to the glycerophospholipid-containing powder of the present invention is 0.01 to 10% by mass, preferably 0.5 to 5% by mass, and more preferably 1 to 4% by mass. is there. When the lubricant (C) is less than 0.01% by mass, tableting troubles such as sticking occur when a glycerophospholipid-containing powder tablet is produced. On the other hand, when the lubricant (C) exceeds 10% by mass, the content of glycerophospholipid cannot be increased. In addition, the solidification prevention and fluidity | liquidity of a glycerophospholipid containing powder can also be improved by containing a lubricant (C).

<Anti-caking agent (D)>
The glycerophospholipid-containing powder of the present invention preferably contains an anti-caking agent (D). The anti-caking agent (D) is a substance for preventing caking during storage of the glycerophospholipid-containing powder and improving fluidity. Examples thereof include fine silicon dioxide, calcium silicate, magnesium silicate, calcium carbonate, calcium phosphate and the like. Of these, fine silicon dioxide is preferred.

  The content of the anti-caking agent (D) with respect to the glycerophospholipid-containing powder of the present invention is not particularly limited, but is preferably 0.01 to 10% by mass, more preferably 0.1 to 5% by mass, More preferably, it is 1-3 mass%. By containing the anti-caking agent (D), the formation of coarse particles due to the caking of glycerophospholipids can be prevented, and the fluidity of the glycerophospholipid-containing powder can be improved.

<Disintegrant (E)>
The glycerophospholipid-containing powder of the present invention preferably contains a disintegrant (E). The disintegrant (E) is a substance that disintegrates the tablet by absorbing water and swelling, or a substance that disintegrates the tablet by generating gas by reacting with water. Examples of the substance that swells by absorbing moisture include polysaccharides such as starch, agar, glycogen, alginic acid, and glucomannan. In addition, insoluble dietary fibers such as cellulose, hemicellulose, and chitin, and cellulose derivatives such as sodium carboxymethylcellulose (CMC) also have swelling properties, and disintegration is recognized. Moreover, carbonate etc. are mentioned as a substance which reacts with a water | moisture content and generate | occur | produces gas.

  The content of the disintegrant (E) in the glycerophospholipid-containing powder of the present invention is not particularly limited, but is preferably 5 to 60% by mass, more preferably 10 to 50% by mass, and particularly preferably 15 to 45% by mass. It is. By containing the disintegrant (E), absorption of glycerophospholipid in the body can be promoted.

As the disintegrant (E), it is particularly preferable to contain insoluble dietary fibers such as cellulose, starch, agar, and CMC.
By containing an insoluble dietary fiber, the adhesiveness of glycerophospholipid powder can be reduced and fluidity | liquidity can be improved. From the viewpoint of reducing the adhesiveness of the glycerophospholipid powder, the content of insoluble dietary fiber with respect to the glycerophospholipid-containing powder of the present invention is preferably 5 to 45 mass%, more preferably 10 to 30 mass%.

  Moreover, since starch, agar, and CMC are excellent in swelling property, when a glycerophospholipid-containing powder is tableted, excellent disintegration property can be imparted to the tablet. The starch content relative to the glycerophospholipid-containing powder of the present invention is preferably 1 to 40% by mass, more preferably 2 to 30% by mass. The content of each component of agar and CMC with respect to the glycerophospholipid-containing powder of the present invention is preferably 0.1 to 10% by mass, more preferably 1 to 5% by mass.

  Furthermore, the glycerophospholipid-containing powder of the present invention can further enhance the disintegration property of the tablet by containing both the unfired coral calcium powder (B) and the disintegrant (E). The total content of the unsintered coral calcium powder (B) and the disintegrant (E) with respect to the glycerophospholipid-containing powder is preferably 50 to 90% by mass, and more preferably 55 to 80% by mass.

<Excipient>
The glycerophospholipid-containing powder of the present invention may contain an excipient. The excipient has no physiological activity and is contained for powdering glycerophospholipid and improving tablet moldability. Here, the excipient in the present invention does not include those having disintegration properties (corresponding to the disintegrant (E)).

  Specific examples of excipients include, for example, monosaccharides such as glucose, fructose and galactose, disaccharides such as lactose, sucrose and maltose, sugars such as maltitol, xylitol, sorbitol, mannitol, reduced isomaltulose and isomalt. Examples include alcohol. Of these, sugar alcohols are more preferred.

  The content of the excipient contained in the glycerophospholipid-containing powder is not particularly limited, but is preferably 2 to 80% by mass, more preferably 5 to 65% by mass, and particularly preferably 10 to 55% by mass. is there. By containing the excipient, the fluidity and powder dispersibility of the glycerophospholipid-containing powder can be improved, and further, when the glycerophospholipid-containing powder is tableted, the moldability of the tablet can be improved.

<Other ingredients>
The glycerophospholipid-containing powder of the present invention comprises the above glycerophospholipid (A), uncalcined coral calcium powder (B), lubricant (C), anti-caking agent (D), disintegrant (E), excipient Besides, inorganic components such as fats and oils, proteins and minerals, functional materials such as vitamins, and the like may be contained.

[Method for producing glycerophospholipid-containing powder]
As a method for producing the glycerophospholipid-containing powder of the present invention, a normal powdering method can be applied. For example, glycerophospholipid (A), uncalcined coral calcium powder (B), disintegrant (E) and excipients are mixed in a specific blending amount, and this is pulverized into powder, extract solution and enzyme The reaction mixture of glycerophospholipid obtained by the reaction is added and mixed with a disintegrant (E) or a part of the excipient, dried and ground, and then unfired coral calcium powder (B) and disintegrant (E) And a method of adding the remainder of the excipient.
The anti-caking agent (D) is preferably added after the glycerophospholipid (A), the disintegrant (E), and the excipient are mixed and pulverized. The lubricant (C) is preferably added before tableting.

  Examples of the drying method include spray drying, hot air drying, drum drying, freeze drying, fluidized bed drying, and continuous vacuum drying. Examples of the grinding method after drying include a grinding method using a cutting mill, a hammer mill, an impact mill, an airflow mill, and the like.

  The average particle size of the glycerophospholipid-containing powder of the present invention is preferably 10 to 1000 μm. The average particle diameter is measured with a dry laser diffraction particle size distribution analyzer. By setting the average particle size to 10 to 1000 μm, the occurrence of tableting troubles such as capping is suppressed, and there is an effect that the mixing with other powder raw materials is excellent. In addition, in this invention, an average particle diameter means the volume reference | standard average particle diameter measured using the dry-type laser diffraction type particle size distribution measuring device (SALD-2100: Corporation | KK Shimadzu Corporation make).

[Uses of powder containing glycerophospholipid]
The glycerophospholipid-containing powder of the present invention is particularly preferably used for the production of glycerophospholipid-containing tablets because it can suppress the occurrence of obstacles during tableting such as sticking and laminating.
Moreover, since the glycerophospholipid-containing powder of the present invention is excellent in fluidity and uniform mixing with other powders, it can also be used in the production of granules, hard capsules and the like.

  The method for producing tablets, granules, hard capsules and the like containing glycerophospholipid-containing powder is characterized by using the glycerophospholipid-containing powder of the present invention and can be produced using a known existing production apparatus.

<Tablet production method>
The method for producing a tablet containing glycerophospholipid-containing powder includes a step of mixing each component constituting the glycerophospholipid-containing powder of the present invention to obtain a mixture, and a step of tableting this mixture with a tableting machine. ing.
Further, in the step of obtaining the mixture, each component may be granulated by a stirring granulator, a fluidized bed granulator or the like.

Further, in the step of obtaining the mixture, other active ingredients may be mixed as long as the content range of each component constituting the glycerophospholipid-containing powder of the present invention is satisfied.
In mixing the components, the mixing order is not particularly limited, but the lubricant (C) is preferably mixed immediately before the tableting step.

  By using the glycerophospholipid-containing powder of the present invention, it is possible to increase the glycerophospholipid content per grain and to eliminate the uneven pattern on the tablet surface.

<Tablets>
Tablets containing glycerophospholipid-containing powder are used for health foods, pharmaceuticals, etc., and the content of glycerophospholipid is preferably 10 to 80% by mass, more preferably 12 to 70% by mass, and particularly preferably. It is 15-60 mass%.

  The tablet hardness is preferably 4 to 30 kgf, more preferably 6 to 20 kgf, and particularly preferably 8 to 15 kgf in consideration of the disintegration property and friability of the tablet.

  The disintegration time of the tablet is preferably 100 minutes or less, more preferably 70 minutes or less, and particularly preferably 40 minutes or less. By shortening the disintegration time, the absorbability of glycerophospholipid in the body can be increased.

  The tablet mass is appropriately set in consideration of ease of drinking, the number of grains taken, and the like, preferably 100 to 1000 mg / grain, more preferably 150 to 500 mg / grain, particularly preferably 200 to 400 mg / grain.

  Further, the tablets may be subjected to film coating or sugar coating as needed.

<Production method of granules and hard capsules>
The method for producing granules and hard capsules includes a step of filling the glycerophospholipid-containing powder of the present invention into a packaging bag such as a three-sided seal or a stick or a hard capsule. Moreover, you may provide the process of mixing powder, such as an excipient | filler and another active ingredient, and obtaining a mixture before the process of filling. By using the glycerophospholipid-containing powder of the present invention, the fluidity is better than the conventional glycerophospholipid powder, so that the filling property is improved and the amount of glycerophospholipid per bag or grain can be increased. .

The present invention will be specifically described below with reference to examples.
[Preparation of powder containing glycerophospholipid]
<Preparation of PS powder>
P1:
Based on the formulation shown in Table 1, PS powder P1 was prepared by the following method.
Reduced isomaltulose as an excipient, cellulose as a disintegrant (E), and water were added to and mixed with glycerophospholipid (A), and then dried by a continuous vacuum drying method. The obtained dried product was pulverized using a power mill (manufactured by Dalton Co., Ltd .: Model P-5). Next, anti-caking agent (D) was mixed with the pulverized dry matter to obtain PS powder P1.

  The glycerophospholipid (A) used as a raw material was prepared by the phosphatidyl group transfer reaction of PC using the method described in JP-A No. 63-36792. The component content of glycerophospholipid (A) is described below.

[Component content of glycerophospholipid (A)]
Phosphatidylcholine (PC) 10% by mass
Phosphatidic acid (PA) 8% by mass
Phosphatidylethanolamine (PE) 7% by mass
Phosphatidylserine (PS) 71% by mass
Other 4% by mass

Details of other materials are as follows.
Anti-caking agent (D):
Fine silicon dioxide: "Silopage # 720" manufactured by Fuji Silysia Chemical Ltd.
Disintegrant (E):
Cellulose: “Theorus ST-100” manufactured by Asahi Kasei Chemicals Corporation
Excipient:
Reduced isomaltulose ... “Powdered Paratinite PNP” manufactured by Mitsui Sugar Co., Ltd.

P2:
“BHN PS-20P” manufactured by BN Co., Ltd. was used. Table 1 shows the composition of the raw materials. In addition, the content of phosphatidylserine (PS) in “BHN PS-20P” is 20 mass%.

<Preparation of glycerophospholipid-containing powder>
Based on the formulation shown in Table 2, the glycerophospholipid-containing powders of Examples 1-7 and Comparative Examples 1-2 were prepared by the following method.
After mixing PS powder P1 or P2, the calcium component and the disintegrant (E), the anti-caking agent (D) was mixed, and then the lubricant (C) was mixed.

Details of the materials used are as follows.
Unbaked coral calcium powder (B):
Coral Ca (unfired, carbonated Ca): “Coral Powder FM” manufactured by Kyowa Hakko Bio. In addition, the calcium carbonate content in “coral powder FM” is 85 mass%.
Calcium component B ':
Eggshell Ca (baked Ca, oxidized Ca): “Eggshell calcium TS-1” manufactured by Taiyo Kagaku Co., Ltd.
Milk Ca (Ca phosphate): “Milk calcium” manufactured by Kyowa Hakko Bio Co., Ltd.

Disintegrant (E):
Cellulose: “Theorus ST-100” manufactured by Asahi Kasei Chemicals Corporation
Starch: “PCS FC-30” manufactured by Asahi Kasei Chemicals Corporation
Agar: “Purification Agar for Disintegration” manufactured by Ina Food Industry Co., Ltd.
CMC: “Sunrose SLD-FM” manufactured by Nippon Paper Industries Co., Ltd.

Anti-caking agent (D):
Fine silicon dioxide: "Silopage # 720" manufactured by Fuji Silysia Chemical Ltd.
Lubricant (C):
Calcium stearate ... "Calcium stearate (vegetable)" manufactured by Taihei Chemical Industry Co., Ltd.

[Preparation of tablets containing glycerophospholipid]
<Preparation of tablets>
The glycerophospholipid-containing powders obtained in Examples 1 to 7 and Comparative Examples 1 and 2 were tableted under the following conditions to obtain glycerophospholipid-containing tablets.
(Tabletting conditions)
Tableting machine: Rotary rotary tableting machine (“PICCOLA” from STEC Co., Ltd.)
Mortar and pestle: 9.0mmφ, R7.5
Mass: 350 mg / grain Turret rotation speed: 15 rpm
Tableting pressure: 10kN

<Evaluation of tablets>
1. Disintegration time Using a disintegration tester (“Disintegration tester TMB-81” manufactured by Toyama Sangyo Co., Ltd.), glycerophospholipid obtained in Examples 1-7 and Comparative Examples 1-2 in 900 mL of water (37 ° C.) A tablet containing the contained powder was put in and the disintegration time was measured. The disintegration of the tablet was confirmed visually. For the disintegration time, the average value of 6 tablets was calculated. The results are shown in Table 3.

2. Hardness Using a tablet hardness meter ("Hardness meter KHT-40N" manufactured by Fujiwara Seisakusho Co., Ltd.), the hardness of the glycerophospholipid-containing tablets obtained in Examples 1 to 7 and Comparative Examples 1 and 2 was measured. For the hardness, an average value of 20 tablets was calculated. The results are shown in Table 3.

3. Sticking 100 glycerophospholipid-containing tablets obtained in Examples 1 to 7 and Comparative Examples 1 and 2 were taken at random, and the number of occurrences of sticking (a phenomenon in which powder adheres to the die and dents were formed on the tablet surface) was counted. And evaluated according to the following criteria. The results are shown in Table 3.
◎: Number of sticking occurrences is 1 or less ○: Number of sticking occurrences is 3 or less ×: Number of sticking occurrences is 4 or more

4). Laminating 100 glycerophospholipid-containing tablets obtained in Examples 1 to 7 and Comparative Examples 1 to 2 were taken at random, and the number of occurrences of laminating (a phenomenon in which tablets peeled in layers) was counted, and the following criteria It was evaluated with. The results are shown in Table 3.
◎: Number of laminating occurrences 3 or less ○: Number of laminating occurrences 5 or less △: Number of laminating occurrences 10 or less ×: Number of laminating occurrences 11 or more

In Table 3, the composition of each component contained in Examples 1-7 and Comparative Examples 1-2 was shown.

  When Table 3 is taken into consideration, it can be seen that Examples 1 to 7 containing unfired coral calcium powder have a small number of sticking and laminating. On the other hand, Comparative Examples 1 and 2 that do not contain unfired coral calcium powder suppress the occurrence of sticking and laminating even if calcium oxide or calcium phosphate is added as a calcium component instead of unfired coral calcium powder. I can't understand.

Next, when Examples 2 to 5 are compared, it can be seen that the effect of suppressing the number of occurrences of laminating is increased when the unfired coral calcium powder is 15% by mass or more.
Further, when Examples 4 and 6 are compared with each other, it is presumed that the incidence of laminating decreases when the glycerophospholipid is 25% by mass or less.

Next, when Example 4 and Comparative Examples 1 and 2 were compared, a decrease in disintegration time was recognized by containing unfired coral calcium powder. That is, it can be said that unfired coral calcium powder has disintegration.
Here, considering the total “(B) + (E)” and the disintegration time of the unfired coral calcium (B) and the disintegrant (E), “(B) + (E)” is 55% by mass or more, It can be seen that the disintegration time is 40 minutes or less, and the disintegration is excellent.

  The glycerophospholipid-containing powder of the present invention can be used for the production of a tablet containing glycerophospholipid at a high concentration. Moreover, the tablet of the present invention containing a high concentration of glycerophospholipid can be used for health foods, pharmaceuticals and the like.

  Furthermore, since the glycerophospholipid-containing powder of the present invention exhibits excellent effects on fluidity and anti-caking, it can be used for health foods, pharmaceuticals, etc. in the form of products such as hard capsules, granules and powders.

Claims (4)

A glycerophospholipid-containing powder containing the following components (A) to (C).
(A) Glycerophospholipid 10-80 mass%
(B) Unbaked coral calcium powder 5-50 mass%
(C) Lubricant 0.01 to 10% by mass further,
(D) Anti-caking agent 0.01 to 10% by mass
The glycerophospholipid-containing powder according to claim 1, comprising: further,
(E) The glycerophospholipid containing powder of Claim 1 or 2 containing a disintegrating agent.   The tablet containing the glycerophospholipid containing powder in any one of Claims 1-3.